Does multimodality therapy improve survival in patients with primary cardiac sarcoma?
Multimodality therapy including surgery, radiation, and chemotherapy is associated with improved survival in patients with primary cardiac sarcoma, though findings may be limited by selection bias.
Cardiac sarcoma is a lethal tumor with an EMS of 25 months. The tumor histology could be a possible predictor of better survival. Although selection bias may have been present, multimodality therapy (surgery, radiation therapy, and chemotherapy) was associated with improved survival.
Randhawa et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: